Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases

Author(s): Lichun Sun, Cui-Yun Yu, L. Vienna Mackey, David H. Coy

Journal Name: Current Topics in Medicinal Chemistry

Volume 16 , Issue 2 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Multiple Gαi protein-coupled somatostatin receptors (SSTRs) are expressed in human kidney and liver tissues. Also, aberrant cAMP signaling has been shown to play a critical role in cysto-genesis and enlargement of the human kidney and liver. Thus, somatostatin (SST) analogs become potential and promising alternatives in treating human polystic kidney disease (PKD) and polycystic liver disease (PLD) via interacting with Gαi protein-coupled SSTRs and further blocking cAMP production. Lanreotide is a synthetic, long-acting SST analog with high binding affinity to SSTR2, and has been clinically approved for the treatment of acromegaly due to excessive growth hormone. Recently, this SST analog has been applied in the treatment of PKD and PLD, and has shown an effective reduction of liver and kidney volume compared to placebo. This review will discuss the discovery of this peptide and its clinical applications in the treatment of PKD/PLD patients.

Keywords: cAMP signaling, Lanreotide, Polycystic kidney disease, Polycystic liver disease, Somatostatin, Somatostatin receptors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 21 September, 2015
Page: [133 - 140]
Pages: 8
DOI: 10.2174/1568026615666150701115157
Price: $65

Article Metrics

PDF: 34